The SG100K has been officially launched by Singapore's Minister for Health Ong Ye Kung on Friday, 16 December 2022
LKCMedicine's Health for Life in Singapore (HELIOS) Study is proud to be a part of the SG100K, a landmark comprehensive population health study of 100,000 Singaporeans over a few decades to identify social, environmental, lifestyle and genetic factors associated with diseases prevalent in Singapore, such as diabetes, hypertension, and cancer.
This multi-institutional effort comes on the back of Singapore's rapidly ageing population, which is contributing to an increasing number of people living with long-term health conditions. Through this, we seek to identify new ways of preventing diseases, and unravel clues that will further the population's health wellbeing.
For a start, SG100K will draw data from 70,000 participants across all ethnic groups enrolled in four existing cohort studies, by LKCMedicine's HELIOS, the Saw Swee Hock School of Public Health, the Singapore Eye Research Institute and Singapore National Eye Centre, and the National Heart Centre Singapore. It aims to recruit the next 30,000 participants within the next two years.
HELIOS Study is a state-of-the-art prospective cohort study, established and led by LKCMedicine, and involving both NHG and Imperial College London. We plan to identify the genetic and environmental factors that underpin development of obesity, diabetes, cardiovascular disease and other complex diseases in Singapore. Our ultimate goal is to use the knowledge generated to develop new approaches for prediction, prevention, early detection and better treatment of these chronic diseases.
Our target to study 10,000 Singaporeans from the three main groups (Chinese, Malay, and Indian) is now well underway. For this study, at the baseline visit, we collect comprehensive, high quality phenotypic information from each participant, comprising health and lifestyle questionnaires, physical measurements, and extensive physiological and imaging data. In addition, biological samples are collected and a panel of biological markers is measured in the blood. Participants will then be followed up long-term to identify changes in health status, including new onset diseases.
The unique and extensive phenotypic measurements collected, together with biological samples and longterm follow-up, will enable investigation of the complex interrelationships between environmental, lifestyle and genetic factors on subsequent disease risk. The HELIOS study provides a powerful resource for medical research across a wide range of disciplines that will be accessible to biomedical researchers worldwide. Now contributing to a bigger national agenda through the SG100K,
SG100K, through HELIOS and its partners, is now recruiting participants. To register your participation or to find out more, please email [email protected].